Sharon Larkin Biography and Net Worth

Director of Senseonics Holdings, Inc. Common Stock

Ms. Larkin was appointed to our Board of Directors in December 2021. Ms. Larkin is a former senior executive of Assertio Therapeutics, Inc., having retired in 2020 as senior vice president, Human Resources and Administration. Ms. Larkin joined Assertio Therapeutics, Inc., in 2017 after retiring from Abbott as divisional vice president, Human Resources, Medical Devices Group, where she provided global human resources leadership for Abbott’s five medical device operating businesses, including Abbott Diabetes Care, Abbott Vascular, Abbott Medical Optics, Abbott Animal Health and Abbott Electrophysiology. Ms. Larkin joined Abbott in 1992 and also held positions of increased responsibility in Abbott’s Nutrition, HealthSystems and Corporate operations. Prior to joining Abbott, Ms. Larkin worked for the Federal Reserve Bank of Atlanta, Jacksonville Branch, where she provided leadership for the branch’s U.S. Treasury securities services and human resources operations. Ms. Larkin received a B.S. in industrial management from the Georgia Institute of Technology.

What is Sharon D. Larkin's net worth?: The estimated net worth of Sharon D. Larkin is at least $82.63 thousand as of September 7th, 2023. Ms. Larkin owns 14,623 shares of Senseonics Holdings, Inc. Common Stock stock worth more than $82,635 as of March 13th. This net worth estimate does not reflect any other investments that Ms. Larkin may own. Learn More about Sharon D. Larkin's net worth.
How do I contact Sharon D. Larkin?: The corporate mailing address for Ms. Larkin and other Senseonics Holdings, Inc. Common Stock executives is 20451 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876. Senseonics Holdings, Inc. Common Stock can also be reached via phone at (301) 515-7260 and via email at [email protected]. Learn More on Sharon D. Larkin's contact information.
Has Sharon D. Larkin been buying or selling shares of Senseonics Holdings, Inc. Common Stock?: Sharon D. Larkin has not been actively trading shares of Senseonics Holdings, Inc. Common Stock within the last three months. Most recently, Sharon Larkin sold 1,544 shares of the business's stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $12.20, for a transaction totalling $18,836.80. Following the completion of the sale, the director now directly owns 14,623 shares of the company's stock, valued at $178,400.60. Learn More on Sharon D. Larkin's trading history.
Who are Senseonics Holdings, Inc. Common Stock's active insiders?: Senseonics Holdings, Inc. Common Stock's insider roster includes Timothy Goodnow (CEO), Sharon Larkin (Director), Douglas Roeder (Director), and Frederick Sullivan (CFO). Learn More on Senseonics Holdings, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Senseonics Holdings, Inc. Common Stock?: In the last twelve months, Senseonics Holdings, Inc. Common Stock insiders bought shares 3 times. They purchased a total of 30,415 shares worth more than $184,790.20. The most recent insider tranaction occured on November, 10th when Director Edelman Steven bought 10,000 shares worth more than $65,500.00. Insiders at Senseonics Holdings, Inc. Common Stock own 3.6% of the company. Learn More about insider trades at Senseonics Holdings, Inc. Common Stock.
Information on this page was last updated on 11/10/2025.

Sharon D. Larkin Insider Trading History at Senseonics Holdings, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/7/2023	Sell	1,544	$12.20	$18,836.80	14,623

Sharon D. Larkin Buying and Selling Activity at Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc. Common Stock Company Overview

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Today's Range

Now: $5.64

$5.58

$5.93

50 Day Range

MA: N/A

2 Week Range

Now: $5.64

$5.25

$15.74

Volume

455,894 shs

Average Volume

504,173 shs

Market Capitalization

$235.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9